1 min read
Add as a preferred source on GoogleCardiol Therapeutics Sets Up $75 Million Share-Sale Program
The company plans to use proceeds to support development of CardiolRx for recurrent pericarditis.
Cardiol Therapeutics announced Tuesday a share-sale program of up to $75 million, giving the company a way to raise money over time for CardiolRx development in recurrent pericarditis.
The at-the-market program will be conducted through Jefferies. It allows Cardiol to sell shares over time at prices prevailing in the market.
Cardiol plans to use the proceeds to support development of CardiolRx for recurrent pericarditis.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.